Synonyms: INSCoV-614 (1B) [WO2021219089]
Compound class:
Synthetic organic
Comment: INSCoV-614 (1B) is one of the most potent of the Mpro inhibitors that are exemplified in Insilico Medicine's patent WO2021219089 [1]. One of Insilico Medicine's Mpro inhibitors (ISM3312, which has been announced as the world's first generative AI-designed COVID-19 drug) has entered clinical trials (in China initially) for potential to treat SARS-CoV-2 infection. ISM3312's chemical structure has not been disclosed (March 2023). Company reports indicate that ISM3312 is suitable for oral or inhalation administration, and has broad spectrum antiviral activity across SARS-CoV-2 variants and other coronaviruses.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Zavoronkovs A, Ivanenkov YA, Zagribelnyy B. (2021)
Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections. Patent number: WO2021219089A1. Assignee: Insilico Medicine Ip Limited. Priority date: 30/04/2020. Publication date: 04/11/2021. |